Skip to main content

Tweets

Prof. Aletaha shares their AutoPiX project - using AI to develop quantitative biomarkers. Something to look forward to since imaging remains an important diagnostic tool in #rheumatology @RheumNow #APLAR25 @rheumarhyme https://t.co/WExT9amazz
1 month ago
Update on Rheumatology workforce shortage in Asia-Pacific Date presented by Dr Ahmad Number of Rheumatologists per 100000 inhabitants across @APLAR_org countries -3 in Japan -1.3 in Australia, Hong Kong, Singapore -0.03 in Pakistan As a result: delayed diagnosis for patients! https://t.co/Hycqtp8BtY
Aurelie Najm @AurelieRheumo ( View Tweet )
1 month ago
Peter Taylor on extra articular manifestations of RA Keep an eye on RA patients’ glomerular function RA patients have increased risk of CKD Systematic review >1million pts Risk Ratio 1.52 @RheumNow #APLAR25 https://t.co/5iZwtmvwSR
Aurelie Najm @AurelieRheumo ( View Tweet )
1 month ago
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/MUKXC0Tw3M
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
πŸ†• Intro to ILD (Part I): the essentials 🫁 Definition & basics πŸ”¬ Key pathology patterns πŸ§‘βš•οΈ Clinical approach πŸ“‹ What rheums need to know ⬇️ Download & learn more: https://t.co/7RzpTDOjwa Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/D9d97bqcD5
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
πŸ’₯ New week, new quiz. Take 90 seconds. Prove you're the rheum news MVP. πŸ“ˆ Track your accuracy 🏁 Race to the top of the leaderboard 🎯 Review what you missed Take the RheumIQ quiz ➑️ https://t.co/CASRQjoYrB https://t.co/FCjkqud0y4
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Lessons Learned in Neuropsychiatric SLE Dr. Sheila Reyes, The Philippines, reports highlights from a session on neuropsychiatric systemic lupus erythematosus, presented at the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Dh1GQnBhvg https://t.co/wX5FgpIq7C
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
PAH diagnosis and management in the context of CTD ILD Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders (CTD), affecting about 25% of PAH patients. CTD-PAH is the second most common cause after the idiopathic form. PAH involves high https://t.co/UgsdYWv02S
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
QD Clinic Video: RA and Bronchiectasis Dr. Jeffrey Sparks, Boston, talks about rheumatoid arthritis and bronchiectasis as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/Y2u3m4rFfj https://t.co/KgrIxXlQo4
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
STOP-RA results published in A&R. 144 at risk, CCP+ pts were enrolled to received HCQ vs PBO for 12 mos, w/ 24 mos F/U. Progression to RA seen in 30.4% on HCQ vs 32.9% on PBO (NS; P=0.52). Also IA, Jt Sxs, severity & adverse events were similar between groups.

Dr. John Cush @RheumNow ( View Tweet )

1 month 1 week ago
TNR: Future Treatment of ILD This Tuesday Night Rheumatology webinar reviewed ACR and EULAR guidelines on interstitial lung disease, with a focus on β€˜where are we now and where are we going?’ in regards to treatment strategies and emerging therapies in ILD care. https://t.co/F1fJhWgR5O
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
AbbVie's US patent protection for Rinvoq (upadacitinib) will run till April 2037. SEC filing shows AbbVie has reached an agreement with generic manufacturers challenging Rinvoq patents. UPA is their 2nd leading product with nearly $3.75 billion worldwide sales in 1st 1/2 of

Dr. John Cush @RheumNow ( View Tweet )

1 month 1 week ago
×